Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02093312
Other study ID # EFFECT.A03.2014
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 2014
Est. completion date April 2015

Study information

Verified date December 2022
Source Copenhagen University Hospital at Herlev
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall objective of the study is to investigate the effect of energy- and protein enriched home delivered meals vs. habitual diet in malnourished patients suffering from cancer on various endpoints.


Description:

Despite the fact that nutritional deterioration has been associated with patients' functional impairment, the effect of individualized nutritional support or counselling to outpatients, focussing on ordinary food, have not yet been thoroughly explored (Ravasco P. et al. 2007). A few studies have investigated the effect of nutritional counselling on quality of life (QoL) in cancer patients after discharge (Ovesen et al. 1993, Persson et al. 2002, Isenring et al. 2004, Ravasco et al. 2005a, Ravasco et al. 2005b). However, there is to our knowledge not conducted any studies examining the effect of home delivered meals on QoL and other endpoints in outpatients suffering from cancer. The overall objective of the study is to measure the effect of energy- and protein enriched home delivered meals vs. habitual diet in malnourished outpatients diagnosed with lung cancer. The intervention diet will consist of optional protein- and energy-dense main and in-between-meals. There will be 22 different main meals and 13 in-between meals to choose between. The meals are prepared by The Nordic Kitchen of Copenhagen University Hospital Herlev. The offered main meals will consist of a selection of warm dishes taken from the ordinary menu. The in-between meals are a collection of the Delights of Herlev (dishes previously shown to increase dietary intake among in-patients). The food will be delivered to the participants' home 3 times per week, and participants can order one warm dish and ad libitum in-between meals for each day.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date April 2015
Est. primary completion date October 2014
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Have a nutritional risk score = 3 according to NRS-2002 (Kondrup J. et al. 2003) - Be diagnosed with lung cancer - Have a life expectancy > 12 weeks - Not plan to loose weight or go on a diet - Not plan to go on vacation for > 2 weeks during the study period - Live at their own home - Live = 25 km from the hospital - Be able to read, write and understand Danish Exclusion Criteria: - Receives food from a food-delivery service - Have food allergies or intolerance - Exclusively receives enteral or parenteral nutrition - Suffers from cognitive impairment e.g. dementia - Is terminal

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Home food-delivery service
A home food-delivery service is offered the intervention group of cancer patients

Locations

Country Name City State
Denmark Herlev University Hsopital Herlev

Sponsors (1)

Lead Sponsor Collaborator
Copenhagen University Hospital at Herlev

Country where clinical trial is conducted

Denmark, 

References & Publications (1)

Leedo E, Gade J, Granov S, Mellemgaard A, Klausen TW, Rask K, Astrup A. The Effect of a Home Delivery Meal Service of Energy- and Protein-Rich Meals on Quality of Life in Malnourished Outpatients Suffering from Lung Cancer: A Randomized Controlled Trial. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Compliance All patients in the intervention group are requested to daily fulfil a compliance sheet during the whole 12-week period, where the intake of intervention dishes will be recorded. Project staff will review the completed sheets together with the study participant at mid-way (week 6) and at the final 12-week visit in order to minimize possible uncertainties. Moreover, eventual side-effects and reasons for non-compliance will be recorded. 1, 6, and 12 weeks
Other Evaluation All the intervention participants will receive an evaluation form in order to assess the acceptability of the offered meals, the food-delivery service, and a possible price they would give for this particular food-delivery service. 12 weeks
Other Effect of social status on total energy- and protein intake Definition of social status: if the participant is living alone or not Baseline
Other Correlation between compliance (intervention group) and Quality of life 12 weeks
Other Correlation between total energy- and protein intake (all participants) and Quality of life 12 weeks
Other Correlation between compliance (intervention group) and Body weight 12 weeks
Other Correlation between compliance (intervention group) and Hand grib strength 12 weeks
Other Correlation between compliance (intervention group) and 30-second chair-stand test 12 weeks
Other Correlation between compliance (intervention group) and Depression score 12 weeks
Other Correlation between compliance (intervention group) and Total energy- and protein intake 12 weeks
Other Correlation between compliance (intervention group) and WHO performance status 12 weeks
Other Correlation between total energy- and protein intake (all participants) and Hand grip strength 12 weeks
Other Correlation between total energy- and protein intake (all participants) and Body weight 12 weeks
Other Correlation between total energy- and protein intake (all participants) and 30 second chair-stand test 12 weeks
Other Correlation between total energy- and protein intake (all participants) and Depression scale 12 weeks
Other Correlation between total energy- and protein intake (all participants) and WHO performance status 12 weeks
Primary Quality of Life To assess the Global QoL, a questionnaire from the European Organization for the Research and Treatment of Cancer (EORTC) QLQ-30, version 3, will be used. This is a validated, cancer-specific questionnaire with a total of 30 questions, looking back at the past week. The scoring of QoL is based on 2 specific questions with response options ranging from 1-7 which indicate very bad to very good. A Danish version of the questionnaire will be used. 6 weeks (change from baseline)
Primary Quality of Life To assess the Global QoL, a questionnaire from the European Organization for the Research and Treatment of Cancer (EORTC) QLQ-30, version 3, will be used. This is a validated, cancer-specific questionnaire with a total of 30 questions, looking back at the past week. The scoring of QoL is based on 2 specific questions with response options ranging from 1-7 which indicate very bad to very good. A Danish version of the questionnaire will be used. 12 weeks (change from baseline)
Secondary Hand grip strength Hand grip strength (in kg) will be measured with a Hydraulic Hand Dynamometer. Participants will be seated with forearms rested on the arms of the chair. They are asked to perform three maximum force trials with their dominant hand and using the second handle position. The test will be repeated within 30 seconds, and the maximum grip score from the three measured values will be used. 6, and 12 weeks (changes from baseline)
Secondary 30-second chair-stand test The 30-second-chair-stand test consist of manually counting the number of sit-stand-sit cycles completed during the 30 seconds of the test. A standard chair (with a seat height of 40cm) with or without a backrest but with armrests will be used. Initially, subject will be seated on the chair with their back in an upright position. They will be instructed to rise after the "1, 2, 3, go" command at their own preferred speed with their arms folded across their chest. If the participant is only able to perform the test by using armrest, the test will be recorded as "modified". 6, and 12 weeks (changes from baseline)
Secondary Body Weight Body weight will be measured to the nearest 0.1 kg following standard procedures (i.e. without shoes, minimal clothing). 6, and 12 weeks (changes from baseline)
Secondary Depression Scale The Center for Epidemiological Studies Depression scale (CES-D) is a short self-report scale designed to measure depressive symptoms (Hann D. et al. 1999). The questionnaire contains 20 items, divided in four domains: Somatic Retarded Activity (7 items), Depressed Affect (5 items), Positive Affect (4 items), and Interpersonal Affect (2 items), and 2 single items that complete the total score. The total score ranges from 0 to 60; a score of =16 indicates a depressed symptomatology. The CES-D has been validated in several samples of cancer patients, and it is often administered to inpatients with cancer (Vodermaier A. et al. 2009). A Danish version of the questionnaire will be used. 6, and 12 weeks (changes from baseline)
Secondary Total energy- and protein intake per day Dietary intake will be assessed by a dietary interview covering patient's dietary intake over the past week. On basis of the dietary interview the total energy and protein intake per day is estimated. A food database with energy- and protein content of various foods is used for the estimation. 6, and 12 weeks (changes from baseline)
Secondary Re-admissions with total length of stay (LOS) Data on re-admissions to the hospital and LOS will be collected from all participants medical charts (hospital medical system OPUS/GS). 12 weeks, and 6 months
Secondary Mortality Data on mortality will be collected from all participants' medical charts (hospital medical system OPUS/GS). 12 weeks, and 6 months
Secondary WHO Performance status 6, and 12 weeks
Secondary Functional-score Using EORTC-QLQ-30 version 3 - looking back at the past week. Out of the 30 questions the functional score is based on 15 specific questions with 4 response options indicating either: not at all, a little, some or a lot. Involves questions related to physical-, role-, emotional-, cognitive- and social functioning. 6 and 12 weeks
Secondary Symptom-score Using EORTC-QLQ-30 version 3 - looking back at the past week. Out of the 30 questions the symptom score is based on 13 specific questions with 4 response options indicating either: not at all, a little, some or a lot. 6 and 12 weeks (changes from baseline)
See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk